Cancer/testis antigen 1 (96-104)

Cancer/testis antigen 1 (96-104) is a synthetic peptide fragment derived from the cancer/testis antigen family, specifically representing amino acids 96 to 104 of the parent protein. As a defined epitope, this peptide is recognized for its restricted expression pattern, typically limited to germ cells and a wide array of tumor types, making it a highly relevant target in tumor immunology and antigen-specific research. Its biochemical properties and immunogenic features have positioned it as a valuable tool in the investigation of tumor-associated antigens, T cell epitope mapping, and the development of immunotherapeutic strategies focused on cancer-specific targets.

Epitope Mapping: In immunological research, the 96-104 fragment of cancer/testis antigen 1 serves as a well-characterized epitope for mapping T cell responses. Researchers utilize this peptide to identify and quantify antigen-specific cytotoxic T lymphocyte (CTL) populations, particularly in studies seeking to elucidate the immunogenic landscape of tumor-associated antigens. By stimulating T cells with the peptide in vitro, scientists can assess the specificity and magnitude of immune recognition, facilitating the development of more precise immunomonitoring assays.

Peptide-Based Vaccine Development: The peptide's defined sequence and immunogenic potential make it a candidate for experimental cancer vaccine platforms. In preclinical models, it is used to evaluate the efficacy of peptide-based vaccines designed to elicit robust cellular immune responses against tumors expressing cancer/testis antigens. Its role in these studies supports the rational design of vaccines that selectively target tumor cells while sparing normal tissues, thus advancing the field of antigen-specific immunotherapy research.

Immunogenicity Assessment: Cancer/testis antigen 1 (96-104) is frequently employed in assays that measure the immunogenicity of tumor antigens. By incorporating the peptide into ELISPOT, intracellular cytokine staining, or tetramer staining protocols, researchers can determine the frequency and functionality of antigen-specific T cells in patient samples or experimental systems. These insights are critical for evaluating immune competence and for optimizing immunotherapeutic approaches that rely on precise antigen recognition.

Adoptive T Cell Therapy Research: The peptide is instrumental in the ex vivo expansion and functional characterization of T cells for adoptive cell therapy investigations. By pulsing antigen-presenting cells with the 96-104 fragment, scientists can selectively expand T cells with high affinity for the cancer/testis antigen, enabling detailed studies of T cell receptor specificity, cytotoxic activity, and persistence. This application supports the optimization of adoptive immunotherapy protocols and the identification of candidate T cell populations for translational research.

Peptide-MHC Binding Studies: The defined nature of the 96-104 peptide allows for its use in peptide-major histocompatibility complex (MHC) binding assays. Researchers leverage this application to characterize the binding affinity and stability of the peptide-MHC complex, which is essential for understanding the molecular interactions underlying antigen presentation. Insights gained from these studies inform the design of improved immunotherapeutic agents and contribute to the broader understanding of antigen processing and presentation mechanisms in cancer biology.

1. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

4. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

5. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation